Discover the most compelling biosimilar articles making waves in the biotech industry for the week of August 18, 2025.
Delve into groundbreaking research unveiling the equivalence of denosumab biosimilar SB16 to the reference product Prolia. This discovery has the potential to revolutionize the treatment landscape for postmenopausal osteoporosis, opening doors to more accessible therapy options for individuals with financial constraints.
Explore a recent study shedding light on the quality attributes of biosimilar monoclonal antibodies compared to their reference products in Japan. By analyzing variations and consistency across multiple product lots, this research aims to establish acceptable quality ranges, bolstering public trust in biosimilars.
Witness the FDA’s expansion of the indication for a tocilizumab biosimilar, now encompassing cytokine release syndrome. Additionally, collaborations between Kashiv BioSciences, MS Pharma, Lupin, and Sandoz are set to pave the way for increased global access to cost-effective biologics, including an omalizumab biosimilar for the Middle East and North Africa.
Experience the emergence of biosimilar LY01011 as a formidable contender in treating bone metastases in solid tumors, showcasing similar efficacy to denosumab. With a comparable safety profile and no unexpected adverse reactions, this biosimilar stands as a promising alternative for patients.
Stay informed about the latest developments in the biosimilar landscape, from the inaugural patent lawsuit involving a petuzumab biosimilar to the introduction of a new ustekinumab biosimilar and an innovative strategy for unbranded biosimilar access. These advancements underscore the dynamic evolution of biosimilars in the healthcare realm.
- Dive deeper into the convergence of clinical, regulatory, and economic perspectives by subscribing to Center for Biosimilars® emails. Gain access to expert insights on evolving treatment paradigms, biosimilar policies, and real-world outcomes that are shaping the future of patient care.
-
Ten years of robust data support the safety of biosimilar filgrastim for donor mobilization, reinforcing its pivotal role in healthcare settings.
-
Learn from thought leaders like Dr. Hillel Cohen on navigating the biosimilar landscape and bridging the gap between science and practice.
-
Witness the promising equivalence of denosumab biosimilar LY01011 to the reference product in treating bone metastases, offering hope for improved patient outcomes.
-
Gain valuable postapproval insights into biosimilar quality attributes from a comprehensive Japanese study, shedding light on crucial aspects of biosimilar development and regulation.
-
Uncover the impact of pricing strategies on insulin biosimilar uptake in the UK, highlighting the intricate relationship between affordability and market adoption.
Embark on a journey through the latest biosimilar breakthroughs, where innovation, collaboration, and patient-centric care converge to redefine the future of biologic therapies. Stay informed, stay empowered, and stay ahead in the dynamic world of biosimilars.
Tags: regulatory, monoclonal antibodies, biosimilars
Read more on centerforbiosimilars.com